Hologic (NASDAQ:HOLX) Updates Q1 Earnings Guidance

Hologic (NASDAQ:HOLX) issued an update on its first quarter earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of $1.00-1.03 for the period, compared to the consensus estimate of $1.03. The company issued revenue guidance of $1.025-1.035 billion, compared to the consensus revenue estimate of $1.04 billion. Hologic also updated its FY 2025 guidance to 4.250-4.350 EPS.

Hologic Trading Up 1.7 %

NASDAQ:HOLX traded up $1.39 on Monday, hitting $83.72. 3,241,693 shares of the stock were exchanged, compared to its average volume of 1,582,480. The stock has a market cap of $19.45 billion, a PE ratio of 28.48, a PEG ratio of 2.93 and a beta of 0.98. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51. The stock has a fifty day moving average of $80.99 and a 200-day moving average of $78.02. Hologic has a fifty-two week low of $66.93 and a fifty-two week high of $84.67.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on HOLX shares. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 target price on shares of Hologic in a research note on Tuesday, October 15th. StockNews.com downgraded Hologic from a “strong-buy” rating to a “buy” rating in a report on Friday, September 27th. Citigroup downgraded Hologic from a “buy” rating to a “neutral” rating and reduced their price target for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. Royal Bank of Canada reissued a “sector perform” rating and issued a $82.00 price target on shares of Hologic in a report on Friday, August 16th. Finally, Mizuho increased their price target on Hologic from $85.00 to $90.00 and gave the company an “outperform” rating in a report on Friday, October 4th. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, Hologic presently has an average rating of “Moderate Buy” and a consensus target price of $87.50.

Insider Activity at Hologic

In related news, insider Brandon Schnittker sold 476 shares of Hologic stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total transaction of $39,560.36. Following the completion of the sale, the insider now owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.75% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.